Sienna Biopharmaceuticals, Inc., a Westlake Village, Calif.-based clinical stage medical dermatology and aesthetics company, completed a $40m Series B financing.
The round was led by existing investors ARCH Venture Partners and Venvest Capital with participation from Partner Fund Management, Altitude Life Science Ventures, and Dr. David Pyott and new investors Fidelity Management & Research Company, investment funds advised by Clough Capital Partners L.P., Omega Fund Management, and others.
The company intends to use the funds to advance its diversified topical biotech pipeline.
Led by Frederick C. Beddingfield III, MD, PhD, President and Chief Executive Officer, Sienna develops therapies to treat inflammatory skin conditions and aesthetic problems.Through its platforms, the company is advancing:
– SNA-120 (TrkA inhibitor) for pruritus and psoriasis (Phase IIb)
– SNA-125 (dual TrkA/JAK3 inhibitor) for atopic dermatitis, psoriasis and pruritus (proof-of-concept), and
– SNA-001 for the treatment of acne vulgaris (pivotal trials) and for the permanent reduction of unwanted light-pigmented hair (pivotal trials).